Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has tapped Mark Ziirsen to become the company’s chief financial officer (CFO) and company secretary, gaining his global experience in senior finance leadership roles with ASX and Nasdaq-listed companies.
The company aims to become a leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands.
Ziirsen has more than 25 years of experience in ASX and Nasdaq-listed companies across life sciences, technology and consumer segments.
"Extensive experience"
“We are pleased to have Mark join our team,” Genetic Technologies CEO Simon Morriss said.
“His extensive experience in leadership roles across multiple industries will add enormous value to our team.”
Ziirsen previously worked with Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited and more recently in roles as an executive, interim or non-executive director for emerging technology-driven businesses, supporting them to scale, grow, transform and raise capital.
GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes.
The company has a proprietary risk stratification platform developed over the past decade to integrate clinical and genetic risk to deliver actionable outcomes to physicians and individuals.